U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07754890) titled 'Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma Phase I/II Trial' on Dec. 08, 2025.
Brief Summary: This is a prospective, single-center phase I/II study, with the purpose of evaluating the efficiency of golidocitinib combined with chidamide in patients with systemically-treated cutaneous T-cell lymphoma. The primary endpoint of the phase I study was to determine the recommended phase II dose (RP2D), while the primary endpoint of the phase II study was the objective response rate (ORR). Secondary endpoints included the complete response (CR) rate, progression-free survival (PFS), duration of response (DOR), overall survival...